Sunday, November 1, 2020

Beware This Dangerous Diabetes Treatment Drug Has Killed Many People

Must Read

BARACK OBAMA : AMERICA WANTS ME BACK FOR A 3RD TERM

He was supposed to retire to a triumphant post-presidency. Then Trump happened. Now, as Jason Zengerle reports, Obama is...

Pennsylvania GOP Sen. Pat Toomey Won’t Run For Re-Election in 2022

Pennsylvania Republican Sen. Pat Toomey has announced that he will not run for reelection in 2022. “I will not be...

Barack Obama Reportedly Skeptical of Joe Biden’s 2020 White House Run

The presidential election is officially less than 30 days away. With that in mind, we thought it would be helpful...

It’s only April’ and this is the third new dangerous Diabetes Treatment drug I’ve already told you about this year. It’s hard enough figuring out how to beat diabetes without having to dodge all these risky new drugs!The story said that this new diabetes drug is a “trailblazer.” But what it’s really doing is leaving a trail of pain and suffering.And there’s no question that the risks of this recently approved Rx for type 2 far outweigh its benefits.It’s called Invokana’ and it’s a “special” kind of med in the same family as another newbie I warned you about in January. It lowers blood sugar by making your kidneys get rid of glucose through the urine.

He warned that the way the Diabetes Treatment drug works’ by eliminating all that glucose in the urine’ “can cause a cascade of adverse events.” These include dehydration’ which can lead to low blood pressure’ dizziness and falls’ and damage to the kidneys and heart.Even having “moderately” reduced kidney function’ he said’ puts people at high risk with this drug.

And the ones most at risk for failing kidneys — diabetics.But that’s not all you would have to worry about when taking Invokana.Wait till you hear what it told the drug’s maker’ Janssen Pharmaceuticals.The FDA actually stated that its usual method of post market review of “adverse events” won’t be “sufficient” to learn if this drug poses a “serious risk” of cancers’ pancreatitis’ bone fractures’ liver damage’ hypersensitivity reactions and “adverse pregnancy outcomes.”

And that’s not the worst…Instead of holding back until more is known about those risks’ the FDA said that it would be okay for Janssen to sell the Diabetes Treatment.drug’ but is “required” to be on the special lookout for all “foreign and domestic” reports of those horrible effects in patients taking Ivokana. And it was given until 2023 to submit a final report about it!Do I have my math right here? You mean to tell me the plan is to tally up the damage toll for 10 years of diabetics taking this risky Diabetes Treatment drug and then take another look?It ordered Janssen to complete a post-market double-blind trial with Invokana to see how many heart attacks’ strokes and fatalities it causes. And they have until 2017 to submit the report on that one.FDA approved that this Diabetes Treatment drug has killed many people.

- Advertisement -

Latest News

BARACK OBAMA : AMERICA WANTS ME BACK FOR A 3RD TERM

He was supposed to retire to a triumphant post-presidency. Then Trump happened. Now, as Jason Zengerle reports, Obama is...

Pennsylvania GOP Sen. Pat Toomey Won’t Run For Re-Election in 2022

Pennsylvania Republican Sen. Pat Toomey has announced that he will not run for reelection in 2022. “I will not be running for reelection in 2022...

Barack Obama Reportedly Skeptical of Joe Biden’s 2020 White House Run

The presidential election is officially less than 30 days away. With that in mind, we thought it would be helpful to remind readers that despite...

LeBron James Walks Off Court With Time Left on Clock During NBA Finals

However, those who are watching got to see Los Angeles Lakers superstar LeBron James throw a hissy fit on Monday night after his team...

AOC Says Dems Must Consider Impeaching Trump, Barr To Stop Supreme Court Nomination

Impeachment would force the U.S. Senate to hold a trial at a time when it has precious few days left on its calendar to...
- Advertisement -

More Articles Like This